The FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for the treatment of chronic hepatitis delta, for which no approved therapies currently exist in the U.S., the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback